American court hearing recordings and interviews

Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!

This is a surprising case that was argued to the U.S. Court of Appeals for the DC Circuit on October 13, 2026. Surprises include the allegation that JP Morgan Chase bank issued the bonds that gave rise to the underlying dispute with the People's Republic of China (PRC) and that the dispute was brought in the United States.

There are also references in the argument to Chinese COVID-19 bonds/Hong Kong bonds and to historical bearer bonds, sometimes referred to during the hearing as antique bonds.

Please Donate via PayPal to support my work podcasting hearings held by American courts to make the hearings more accessible.

Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!

This is the official court recording of the October 14, 2026 argument to the U.S. Court of Appeals concerning U.S. President Donald Trump's deployment of the National Guard to reduce crime in Washington, DC (DC v Donald Trump).

Please Donate via PayPal, if you can, to support my work podcasting hearings held by American courts to make the hearings more accessible.

Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!

... and link to the Court of Appeals ruling: https://ww3.ca2.uscourts.gov/decisions/OPN/25-567_opn.pdf

---

Listen to the argument before the U.S. Court of Appeals for the Second Circuit held January 26, 2026. The Court of Appeals took the matter under advisement. Then, a few months later, the three- judge panel of judges assigned to the appeal ruled in favor of the Federal Deposit Insurance Corporation (the FDIC), as receiver for Silicon Valley Bank and Silicon Valley Bridge Bank, N.A. The ruling is reflected in the written opinion handed down September 9, 2026: https://ww3.ca2.uscourts.gov/decisions/OPN/25-567_opn.pdf

The Court of Appeals held that the FDIC was not required to file a proof of claim in the SVB bankruptcy proceedings in the Southern District of New York, to preserve the FDIC's defensive setoff rights in a lawsuit in California.

Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!

This is an audio recording of the hearing held October 6, 2023 by the U.S. Court of Appeals for the Ninth Circuit, a public record posted to the website of the court as an MP3 file for public download. The recording is made more accessible to the public thanks to technological innovations of podcasting such as providing no cost closed captioning text accompanying the audio recordings, for people who are hearing impaired. Also podcasting makes audio recordings of court hearings accessible to many other people including people who can better focus on what they are listening to when they are reading along and people who are visually impaired.

The U.S. Supreme Court is scheduled to hear arguments on October 7, 2026 in the further appeal in this case, which concerns permitting of munition explosions in Guam under NEPA.

Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!

After the September 16 hearing in the Noble Supply & Logistics bankruptcy proceedings, counsel for the bankrupt companies (Noble) and the government circulated to the bankruptcy court competing proposed orders for the court to enter. The parties were endeavoring to track the bankruptcy court's ruling on the record of September 16 but could not agree on terms. This hearing of September 18 followed to work out terms for a bankruptcy court order reflecting the court's earlier ruling. Thereafter the bankruptcy court entered an order clarifying and implementing the court's earlier ruling.

https://veritaglobal.net/noble/document/2611369260918000000000009

The bankruptcy court also declined, on the record and in the order the court entered, the government's request for a stay pending appeal, letting counsel for the government know during the hearing that counsel could seek a stay "across the street" - in other words, from an appellate court, if the government appeals the bankruptcy court order in favor of the bankrupt companies.

Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!

This is the hearing held (and filed on the bankruptcy court's docket on PACER) on September 16, 2026,

To access this file and other filings in the Noble Supply & Logistics chapter 11 bankruptcy case, try to link to the free docket: Noble Supply & Logistics, LLC, et al.

Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!

The hearing was held September 1, 2026 and the audio recording of the hearing was docketed in the Noble Supply & Logistics bankruptcy proceedings thereafter. For more information about the bankruptcy case see: https://veritaglobal.net/noble

Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!

For more information about the bankruptcy cases see https://cases.stretto.com/SVM/

(Bankruptcy Case Numbers and Bankruptcy Debtor Names):

26-10966

Searles Valley Minerals Inc.

26-10967

Trona Railway Company LLC

26-10968

Searles Domestic Water Company LLC

Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!

Per BioXcel's press release:

BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals

Aug 28, 2026

PDF Version

BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders

Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process

BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations

NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it has entered into an asset sale agreement with Teva Pharmaceuticals International GmbH (“Teva”), a subsidiary of Teva Pharmaceutical Industries Ltd., for substantially all of the Company’s assets. This includes IGALMI® (dexmedetomidine) sublingual film and the related pending supplemental New Drug Application of BXCL501 for potential at-home (outpatient) use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Concurrent with the execution of the asset sale agreement, BioXcel Therapeutics and its subsidiaries, OnkosXcel Therapeutics, LLC and OnkosXcel Employee Holdings, LLC, have commenced voluntary Chapter 11 proceedings in the U.S. Bankruptcy Court for the District of Delaware (the “Court”) to facilitate a court-supervised sale process, which is expected to include the auction of substantially all of the Company’s assets.

To anchor the sale process, Teva will serve as the sole “stalking horse bidder” for the sale of the assets contemplated by the asset sale agreement. A stalking horse asset sale agreement establishes a strong baseline offer and is intended to help maximize value for all stakeholders through the Chapter 11 auction process.

“Following a comprehensive review of strategic alternatives, we believe this option provides a clear framework to pursue a value-maximizing transaction” said Vimal Mehta, Ph.D., Chief Executive Officer of BioXcel Therapeutics. “Our priority is to execute a disciplined and efficient sale process while supporting all of our stakeholders and continuing to support the sNDA with a PDUFA date of November 14, 2026. We are pleased to have a signed agreement with a leading pharmaceutical company to serve as stalking horse bidder in the process, underscoring the strategic interest in our assets and in IGALMI®....”

For the rest of the BioXcel press release see: https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-enters-asset-sale-agreement-teva

For more information about the BioXcel bankruptcy/sale including the bankruptcy petitions and information about company assets and liabilities see: https://cases.stretto.com/bioxcel/ Typically, in situations such as these, there is a proposed buyer referred to as a stalking horse, and there is also an opportunity for other parties to come forward and bid on the assets.

Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!

--